PENTOXIFYLLINE SR TABLET (EXTENDED-RELEASE)

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

PENTOXIFYLLINE

থেকে পাওয়া:

AA PHARMA INC

এটিসি কোড:

C04AD03

INN (আন্তর্জাতিক নাম):

PENTOXIFYLLINE

ডোজ:

400MG

ফার্মাসিউটিকাল ফর্ম:

TABLET (EXTENDED-RELEASE)

রচনা:

PENTOXIFYLLINE 400MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100/500

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

HEMORRHEOLOGIC AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0115837001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2012-07-09

পণ্য বৈশিষ্ট্য

_PENTOXIFYLLINE SR _
_Page 1 of 24_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
PENTOXIFYLLINE SR
Pentoxifylline Sustained-Release Tablets
Sustained-Release Tablets, 400 mg, Oral
House Standard
Vasoactive Agent
AA PHARMA INC.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Initial Authorization:
July 10, 2012
Date of Revision:
JAN 27, 2022
Submission Control Number: 254072
_ _
_PENTOXIFYLLINE SR _
_Page 2 of 24_
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 1.2 Geriatrics
01/2022
2 CONTRAINDICATIONS
01/2022
4 DOSAGE AND ADMINISTRATION
01/2022
7 WARNINGS AND PRECAUTIONS
01/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
..............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
......................................................... 5
4.4
Administration
.........................................................................................